HRMY Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. (HRMY) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $802.1K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 3,746 | $37.15 | $139.2K | 24,521 −13.3% of holding | |
| Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 20,961 | $35.92 | $752.8K | None left | |
| Dayno Jeffrey M. 2 fills | PRESIDENT, CEO | Sell 10b5-1 | 25,933 | $40.11 | $1.0M | None left | |
| Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 20,000 | $39.54 | $790.9K | None left | |
| Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 3,427 | $35.00 | $119.9K | None left |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.